After a dedicated debate during the May plenary session (see EUROPE B12722A8), the European Parliament will adopt, on Wednesday 9 June, a resolution on the controversial issue of intellectual property rights (IPR) for vaccines and therapeutic treatments for Covid-19.
On Friday 4 June, the European Commission called for the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), including the granting of compulsory licences by a Member State to...